Athira Pharma Balansräkning Hälsa

Finansiell hälsa kriterier kontrolleras 4/6

Athira Pharma har ett totalt eget kapital på $44.8M och en total skuld på $0.0 vilket ger sin skuldsättningsgrad till 0%. Dess totala tillgångar och totala skulder är $58.8M respektive $13.9M.

Viktig information

Skuldsättning i förhållande till eget kapital

US$0

Skuld

Räntetäckningsgrad	n/a
Kontanter	US$51.28m
Eget kapital	US$44.84m
Summa skulder	US$13.94m
Totala tillgångar	US$58.78m

Nya uppdateringar om finansiell hälsa

Recent updates

Will Athira Pharma (NASDAQ:ATHA) Spend Its Cash Wisely?

Feb 16

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

Nov 02

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

May 29

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans?

Jan 04

Athira Alzheimer's drug trial gets monitoring panel nod to continue after efficacy analysis

Oct 17

Athira Pharma GAAP EPS of -$0.65

Aug 15

We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Aug 09

Athira Pharma: The Market Is Missing A Potential New Alzheimer's Drug

Jun 22

Companies Like Athira Pharma (NASDAQ:ATHA) Are In A Position To Invest In Growth

May 08

We're Not Very Worried About Athira Pharma's (NASDAQ:ATHA) Cash Burn Rate

Jan 11

Athira Pharma: What, Exactly, Did The CEO Do?

Jun 29

Athira Pharma falls after the decision to place CEO on temporary leave

Jun 17

Athira surges after Jefferies estimated 50% gain on FDA approval for Biogen’s Alzheimer’s therapy

Jun 07

We Think Athira Pharma (NASDAQ:ATHA) Can Afford To Drive Business Growth

May 24

We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Feb 08

Athira: Early Stage Alzheimer's Therapeutics With An Interesting Approach

Jan 11

Here's What Athira Pharma, Inc.'s (NASDAQ:ATHA) Shareholder Ownership Structure Looks Like

Dec 18

Athira Pharma nabs research grant of $15M from NIH

Dec 08

Athira Pharma reports Q3 results

Nov 12

Analys av finansiell ställning

Kortfristiga skulder: ATHA s kortfristiga tillgångar ( $54.8M ) överstiger dess kortfristiga skulder ( $13.1M ).

Långfristiga skulder: ATHA s kortfristiga tillgångar ( $54.8M ) överstiger dess långfristiga skulder ( $803.0K ).

Skuld till eget kapital Historik och analys

Skuldnivå: ATHA är skuldfri.

Minska skulden: ATHA har för närvarande inga skulder men vi kan inte jämföra med 5 år sedan eftersom vi inte har några uppgifter för den perioden.

Balansräkning

Analys av kontantbanan

För företag som i genomsnitt har gått med förlust tidigare bedömer vi om de har minst 1 års kassaflöde.

Stabil Cash Runway: ATHA har mindre än ett år av cash runway baserat på dess nuvarande fria kassaflöde.

Prognos Cash Runway: ATHA har mindre än ett år av kontanter om det fria kassaflödet fortsätter att minska med historiska takter på 37.1 % varje år

Upptäck friska företag

Företagsanalys och finansiella data Status

Uppgifter	Senast uppdaterad (UTC-tid)
Analys av företag	2025/03/03 11:23
Aktiekurs vid dagens slut	2025/03/03 00:00
Intäkter	2024/12/31
Årlig intjäning	2024/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

Paket	Uppgifter	Tidsram	Exempel US-källa
Företagets finansiella ställning	10 år	Resultaträkning Kassaflödesanalys Balansräkning	SEC Form 10-K SEC Form 10-Q
Analytikernas konsensusuppskattningar	+3 år	Prognos för finansiella poster Analytikernas prismål	Rapporter från analytiker Blue Matrix
Marknadspriser	30 år	Aktiekurser Utdelningar, splittar och åtgärder	ICE Marknadsdata SEC Form S-1
Ägarskap	10 år	Största aktieägare Insiderhandel	SEC Formulär 4 SEC Formulär 13D
Förvaltning	10 år	Ledningsgrupp Styrelse och verkställande direktörer	SEC Form 10-K SEC Form DEF 14A
Viktiga utvecklingstendenser	10 år	Företagsmeddelanden	SEC Formulär 8-K

^* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om den analysmodell som används för att generera denna rapport finns på vår Github-sida, vi har också guider om hur man använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Athira Pharma, Inc. bevakas av 9 analytiker. 4 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

Analytiker	Institution
Esther Lannie Hong	Berenberg
Thomas Shrader	BTIG
Corinne Johnson	Goldman Sachs

Athira Pharma Balansräkning Hälsa

Finansiell hälsa kriterier kontrolleras 4/6

Viktig information

Nya uppdateringar om finansiell hälsa

Athira Pharma Receives Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Global Select Market

Athira Pharma Receives Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Global Select Market

Will Athira Pharma (NASDAQ:ATHA) Spend Its Cash Wisely?

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans?

Recent updates

High number of new directors

Athira Pharma Receives Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Global Select Market

Athira Pharma Receives Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Global Select Market

Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases

Price target decreased by 46% to US$4.00

Athira Pharma, Inc. Announces Topline Results from Phase 2/3 Lift-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer's Disease

Athira Pharma Announces Last Patient Completed Lift-Ad Clinical Trial of Fosgonimeton in Mild-To-Moderate Alzheimer’s Disease

New major risk - Financial position

Independent Chairwoman of the Board recently bought US$100k worth of stock

Athira Pharma, Inc. Announces Proposed Settlement of Stockholder Derivative Action

Athira Pharma, Inc. Appoints Javier San Martin, M.D., as Chief Medical Officer

Athira Pharma, Inc. Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease

Athira Pharma, Inc., Annual General Meeting, May 23, 2024

New minor risk - Market cap size

Will Athira Pharma (NASDAQ:ATHA) Spend Its Cash Wisely?

Athira Pharma, Inc. Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)

Athira Pharma, Inc. Announces Hans Moebius Retires as Chief Medical Officer

Athira Pharma, Inc. Announces Hans Moebius Retires as Chief Medical Officer

Price target increased by 23% to US$9.25

Athira Pharma, Inc. Presents Preclinical Data Highlighting Fosgonimeton's Neuroprotective Effects Against Amyloid-B-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer's Disease

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

New minor risk - Market cap size

Athira Pharma, Inc. Appoints Andrew Gengos as Chief Financial Officer

Athira Pharma, Inc. Presents Phase 2 Clinical Data Correlating Improvements in Biomarkers of Neurodegeneration and Neuroinflammation with Improvements in Measures of Cognition and Function in Alzheimer’s Disease

CFO & Chief Business Officer recently bought US$192k worth of stock

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

Athira Pharma, Inc. Announces the Appointment of Andrew Gengos as Chief Business Officer

Athira Pharma, Inc. Announces CFO Changes

Independent Director recently bought US$60k worth of stock

Price target decreased by 33% to US$7.83

Athira Pharma Announces Promotion of Kevin Church to Chief Scientific Officer

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans?

Chief Financial Officer recently bought US$142k worth of stock

Athira Pharma, Inc. Announces Publication of Fosgonimeton Preclinical Results in Neurotherapeutics

Independent Chairwoman of the Board recently bought US$99k worth of stock

Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND

Price target increased to US$11.75

High number of new and inexperienced directors

Athira Pharma Advances Phase 2/3 Lift-Ad Clinical Study of Fosgonimeton in Mild-To Moderate Alzheimer's Patients Following Independent, Unblinded Interim Analysis

Price target increased to US$11.75

Athira Alzheimer's drug trial gets monitoring panel nod to continue after efficacy analysis

Athira Pharma, Inc. Provides Update on Plans for Ongoing LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients

Athira Pharma GAAP EPS of -$0.65

We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Athira Pharma Presents Data from ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients at the Alzheimer's Association International Conference 2022

Price target decreased to US$15.40

Athira Pharma, Inc. Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease

Athira Pharma: The Market Is Missing A Potential New Alzheimer's Drug

Athira Pharma, Inc. Announces New Board Appointments

Richard A Kayne Issues Letter to Shareholders of Athira Pharma Inc

Athira Pharma Extends Ongoing Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of Fosgonimeton (ATH-1017) for Mild to Moderate Alzheimer’s Disease

Companies Like Athira Pharma (NASDAQ:ATHA) Are In A Position To Invest In Growth

Richard A Kayne Communicates with Athira Pharma Inc

Richard A Kayne Communicates with Athira Pharma Inc

High number of new and inexperienced directors

Richard A. Kayne Files an Investor Presentation to Shareholders of Athira Pharma

Richard A. Kayne Files an Investor Presentation to Shareholders of Athira Pharma

Richard A. Kayne Provides Information to Shareholders of Athira Pharma Inc

Athira Pharma, Inc., Annual General Meeting, May 19, 2022

Athira Pharma, Inc. Doses First Subject in Phase 1 Clinical Trial of HGF/MET Positive Modulator, ATH-1020, an Orally Available Small Molecule for Neuropsychiatric Conditions

Independent Chairman of the Board recently bought US$105k worth of stock

Richard A. Kayne Sends Provides Information to Shareholders of Athira Pharma Inc

Athira Pharma, Inc. Presents Preclinical Data of Fosgonimeton (ATH-1017) and ATH-1020 at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting

Athira Pharma, Inc. Announces Publication of Phase 1 Results for Fosgonimeton (ATH-1017) in The Journal of Alzheimer's Disease

Price target increased to US$39.67

Athira Pharma, Inc. Appoints Grant Pickering to Its Board of Directors

Athira Pharma Announces Initiation of Patient Dosing in Shape, a Phase 2 Clinical Trial of ATH-1017

We're Not Very Worried About Athira Pharma's (NASDAQ:ATHA) Cash Burn Rate

Price target decreased to US$33.75